
Cellanome, a synthetic biology firm, leverages a multi-omics platform for innovative molecular solutions.
Cellanome is a synthetic biology company focused on developing an automated multi-omics platform to enhance the understanding of individual cell behaviors, interactions, and functions. The platform integrates molecular biology, biochemistry, microfluidics, integrated sensors, and genome sequencing to enable researchers to conduct iterative live cell phenotypic and functional assays at scale. This technology broadens the range of cell types and functions accessible to scientists, facilitating novel solutions to complex biological challenges.
Cellanome has made significant strides in the field of synthetic biology by providing tools that allow for massively parallel analysis of cellular responses. This innovation has empowered researchers to explore new questions and gain deeper insights into cellular mechanisms. The company's impact is evident in its ability to link specific cellular responses to various stimuli, advancing the capabilities of biological research and development.

Character Biosciences

Atsena Therapeutics

Geneseeq

Genapsys

Nordic Bioscience

Inscripta

Think Bioscience

Synlife
synlifebio.com

Celldom
celldom.com

Partillion Bioscience
partillion.com

Slingshot Biosciences
slingshotbio.com

Octant
octant.bio

Asimov
asimov.com

Mimetics
mimeticsbiosci.com

Flexomics
flexomics.com

Antheia
antheia.bio

CytoTronics
cytotronics.com

Syncell
syncell.com

CellChorus
cellchorus.com

Mission Bio
missionbio.com
Companies similar to Cellanome include Character Biosciences, Atsena Therapeutics, Geneseeq and Nordic Bioscience.
Cellanome was founded in 2020.
Cellanome's headquarters is located in Foster City, CA, US.
Cellanome's most recent funding round was for $40.7M (USD) in August 2022.
As of Aug 5, 2022, Cellanome has disclosed funding of $63.7M (USD).
Cellanome has 33 employees as of Feb 5, 2024.